[go: up one dir, main page]

WO1986000529A1 - Preparation antivirale et son procede de production - Google Patents

Preparation antivirale et son procede de production Download PDF

Info

Publication number
WO1986000529A1
WO1986000529A1 PCT/HU1985/000040 HU8500040W WO8600529A1 WO 1986000529 A1 WO1986000529 A1 WO 1986000529A1 HU 8500040 W HU8500040 W HU 8500040W WO 8600529 A1 WO8600529 A1 WO 8600529A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
gumboro
preparation
attenuated
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU1985/000040
Other languages
English (en)
Inventor
László CSATÁRY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO1986000529A1 publication Critical patent/WO1986000529A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • object of the invention is a biological preparaion for the treatment of virus infections
  • object of the invention is also the procedure of its production
  • further objects are the use of atte ed Gumboro virus or Gumboro virus vaccine for treatment of virus infections in humans, and the application of these preparations to humans.
  • the preparation is suitable for the treatment of practically any virus infection, and is particularly efficient against Herpesvirus infections, plastic diseases, aphthostomatosis and collagen diseases.
  • Hepatitis virus infection damages the parenchyma. It has three different forms, known as epidemic hepatitis (hepatitis A virus infection), hepatitis (hepatitis B virus infection) and non-A-non-B (or C) hepatitis, a condition presumably caused by a hepatitis virus other than A or B.
  • the clinical course of the hepatitis A infection is relatively mild. Latency is usually 10-28 days. The patient is confined to bed for 30-45 days, and disability lasts still longer. The infection evokes specific immunity to further hepatitis A infection but no vaccine is available for prevention. Hepatitis B infection takes a more serious clinical course, and its latency is also longer, 50 - - 160 days.
  • Virus B is much more resistant to thermic and chemical influences than virus A and most other viruses. Hepatocellular carcinoma is a frequent sequel to hepatitis B infection. This infection does not, as a rule, evoke an immune response. A vaccine prepared from the blood of convalescents is available against hepatitis B, but it has been little used on account of its possible side effects (AIDS) and high price.
  • AIDS side effects
  • the purpose of the present invention has therefore been to develop a biological preparation suitable for the therapy and control of viral hepatitis.
  • the object of the invention is the development, and method of production of an antiviral preparation containing attenuated Gumboro virus, with or without an adjuvant potentiating the latter's act.ion.
  • Object of the invention is also the application of the above preparations, and the use of attenuated Gumboro virus, in human therapy.
  • the Gumboro virus vaccine is known and widely used in the veterinary field.
  • the Gumboro disease is an acute viral disease of chickens, affecting them mainly at the age of 3-6 weeks. Its main symptoms are watery diarrhea, hyper trophy of the bursa of Pabricius, and inflammation of the lymphoid organs.
  • the Gumboro disease also known as infectious bursitis of chickens, was first described by Congreve in 1957. The disease also occurs in European countries, among others in Hungary.
  • the causal agent of the disease an enterovirus, is noted for its high resistance.
  • the symptoms set in abruptly after a latency of 2-4 days, and usually subside after a week; most losses occur between days 3 and 5 of the clinical course. In the outbreaks studied, morbidity was 1-30 %, and mortality was 4-5 % .
  • the Gumboro vaccine i.e. the attenuated Gumboro virus used by us is prepared by methods known from the literature.
  • a freeze-dried vaccine is prepared from attenuated virus propagated in primary or secondary fibroblast cultures from 10-11-day chick embryos.
  • Sterile virus material of at least 10 TCID 50 /0.1 ml titre may be used for production of the vaccine, as prescribed in the Pharm. Hung. VI.
  • To the sterile virus material is added 50 % skim milk, and 2 ml amounts of the vaccine are distributed to 10 ml vials for freeze-drying.
  • the expiration time of the vaccine is one year when stored in sealed vials at +4 oC. Safety testing is performed in 15 SPP chickens aged 3 weeks; the birds must not show symptoms within 14 days of vaccination.
  • the freeze-dried vaccine is delivered in packing units of 100, 200, 500 and 1000 doses, and is used for prevention of the Gumboro disease. It Is administered orally, in the drinking water.
  • the vaccine described above is used as active substance of the preparation which is the object of the invention.
  • the attenuated virus itself or any solution (e.g. a physiological solution) thereof can also be used for that purpose.
  • the Gumboro virus is non-pathogenic for man even in its virulent state. Its attenuated form is doubly safe for humans.
  • the Gumboro vaccine - the object of the invention - is prepared exclusively from attenuated virus.
  • the underlying mechanism of its antiviral action is presumably an interference phenomenon, more precisely a competition between the infecting virus and the vaccine virus.
  • chlorpromazine promethazine, methophenazine, aminopromazine and similar compounds can be used as potentiating agents.
  • the attenuated virus, component of the preparation which is the object of the invention should preferably be adsorbed onto a common carrier substance.
  • a freeze-dried vaccine with carrier proved to be the most advantageous, but the preparation can also be delivered in other forms, such as solution, suppository, capsule, emulsion, suspension, etc.
  • the applied dose depends on the patient treated, actual composition of the preparation, stage of disease and virus strain used.
  • the attenuated virus 1000 to 5000 U should be used daily either in a single dose or in 2-5 divided doses. Administration on 6 consecutive days is usually sufficient for full effect.
  • Application may be oral or rectal, but where local therapy is required, as in Herpesvirus infections, the preparation car. be applied in the form of solution or ointment.
  • the dosage also depends on patient, stage of infection and type of causative agent.
  • chlorpormazine may be administered, at the daily dose level of 10-15 mg.
  • a synergistic preparation should contain 10-100 mg chlorpromazine for each 1000 U of attenuated virus.
  • the preparations which are the object of the invention have been tested in many animal experiments and human trials, and developed in these a practically 100 % therapeutic effect against both hepatitis A and B, without any toxic side effect. They are suitable not only for symptomatic treatment, but also for prophylactic use: the contact persons of hepatitis A patients, given Gumboro virus preventively within 5 weeks of latency, did not contract the infection.
  • Herpesvirus infections such as herpes simplex I, II, herpes zooster., cytomegalovirus disease, infectious mononucleosis (Epstein-Barr virus);

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Préparation biologique pour le traitement d'infections virales, et son procédé de production. Le principe du procédé consiste à combiner le virus Gumboro atténué avec au moins un porteur enregistré. La préparation objet de la présente invention se caractérise en ce qu'elle comprend le virus Gumboro atténué.
PCT/HU1985/000040 1984-07-02 1985-07-01 Preparation antivirale et son procede de production Ceased WO1986000529A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU833616A HU197846B (en) 1984-07-02 1984-07-02 Process for producing therapeutic composition suitable for treating virus infections
HU3616/83 1984-07-02

Publications (1)

Publication Number Publication Date
WO1986000529A1 true WO1986000529A1 (fr) 1986-01-30

Family

ID=10964798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU1985/000040 Ceased WO1986000529A1 (fr) 1984-07-02 1985-07-01 Preparation antivirale et son procede de production

Country Status (4)

Country Link
EP (1) EP0188499A1 (fr)
AU (1) AU4549385A (fr)
HU (1) HU197846B (fr)
WO (1) WO1986000529A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
US7056689B1 (en) 1993-04-30 2006-06-06 Wellstat Biologics Corporation Methods of treating and detecting cancer using viruses
WO2008068661A1 (fr) * 2006-12-01 2008-06-12 Hepc Biotechnológiai Kutató És Fejleszto Kft. Compositions et procédés pour le traitement de l'hépatite virale
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US8043612B2 (en) 1997-10-09 2011-10-25 Wellstat Biologics Corporation Infection and treatment of neoplasms with vesicular stomatitis virus
US8105578B2 (en) 1997-10-09 2012-01-31 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US8377450B2 (en) 2009-11-30 2013-02-19 United Cancer Research Institute Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2188593T3 (es) * 1992-03-24 2003-07-01 United Cancer Res Inst Vacuna que contiene un virus vivo.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3548055A (en) * 1969-05-14 1970-12-15 Research Corp Infectious bursal disease vaccine
AT308967B (de) * 1970-09-12 1973-07-25 Behringwerke Ag Verfahren zur Herstellung einer Lebendvaccine
US3885011A (en) * 1971-12-29 1975-05-20 Janssen Pharmaceutica Nv Vaccine adjuvants
DD143793A1 (de) * 1979-03-12 1980-09-10 Ursula Schmidt Verfahren zur herstellung eines impfstoffs gegen die infektioese bursitis der huehner

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3548055A (en) * 1969-05-14 1970-12-15 Research Corp Infectious bursal disease vaccine
AT308967B (de) * 1970-09-12 1973-07-25 Behringwerke Ag Verfahren zur Herstellung einer Lebendvaccine
US3885011A (en) * 1971-12-29 1975-05-20 Janssen Pharmaceutica Nv Vaccine adjuvants
DD143793A1 (de) * 1979-03-12 1980-09-10 Ursula Schmidt Verfahren zur herstellung eines impfstoffs gegen die infektioese bursitis der huehner

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
US7056689B1 (en) 1993-04-30 2006-06-06 Wellstat Biologics Corporation Methods of treating and detecting cancer using viruses
US7736640B2 (en) 1993-04-30 2010-06-15 Wellstat Biologics Corporation Methods of treating and detecting cancer using viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US8043612B2 (en) 1997-10-09 2011-10-25 Wellstat Biologics Corporation Infection and treatment of neoplasms with vesicular stomatitis virus
US8105578B2 (en) 1997-10-09 2012-01-31 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
WO2008068661A1 (fr) * 2006-12-01 2008-06-12 Hepc Biotechnológiai Kutató És Fejleszto Kft. Compositions et procédés pour le traitement de l'hépatite virale
US8398969B2 (en) 2006-12-01 2013-03-19 HepC Biotechnológiai Kutató és Fejlesztö Kft. Compositions and methods for the treatment of viral hepatitis
US8377450B2 (en) 2009-11-30 2013-02-19 United Cancer Research Institute Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Also Published As

Publication number Publication date
HU197846B (en) 1989-06-28
EP0188499A1 (fr) 1986-07-30
AU4549385A (en) 1986-02-10
HUT47223A (en) 1989-02-28

Similar Documents

Publication Publication Date Title
Baer et al. A model in mice for the pathogenesis and treatment of rabies
Takahashi et al. Live vaccine used to prevent the spread of varicella in children in hospital
Lodmell et al. Cellular immunity to herpes simplex virus mediated by interferon
CA2080477A1 (fr) Vaccin administre par voie orale, a base d'antigenes fixes a la surface de globules rouges
HU202119B (en) Adjuvant mixture and process for producing vaccine comprising same
Kaplan et al. Pathogenesis of rabies in immunodeficient mice
Biront et al. Inhibition of virus replication in the tonsils of pigs previously vaccinated with a Chinese strain vaccine and challenged oronasally with a virulent strain of classical swine fever virus
WO1986000529A1 (fr) Preparation antivirale et son procede de production
Babiuk et al. Use of recombinant bovine alpha 1 interferon in reducing respiratory disease induced by bovine herpesvirus type 1
Morahan et al. Immune responses to vaginal or systemic infection of BALB/c mice with herpes simplex virus type 2
Muldoon et al. Effect of isoprinosine against influenza and some other viruses causing respiratory diseases
Wiktor et al. Role of interferon in prophylaxis of rabies after exposure
McKercher et al. Foot-and-mouth disease in swine: I. The immune response of swine to chemically-treated and non-treated foot-and-mouth disease virus
Lerner et al. Concentrations of idoxuridine in serum, urine, and cerebrospinal fluid of patients with suspected diagnoses of Herpesvirus hominis encephalitis
WO1986000811A1 (fr) Preparations therapeutiques pour le traitement de certaines maladies d'origine virale ou autre et leur production
Shipkowitz et al. Antiviral activity of a bis-benzimidazole against experimental rhinovirus infections in chimpanzees
US5215745A (en) Method for treating viral diseases with attenuated virus
Plotkin et al. Prevention of rabies in man
Zwartouw et al. Oral chemotherapy of fatal B virus (Herpesvirus simiae) infection
Christy et al. Safety and immunogenicity of live attenuated rhesus monkey rotavirus vaccine
Webster et al. Vaccination as a strategy to reduce the emergence of amantadine-and rimantadine-resistant strains of A/Chick/Pennsylvania/83 (H5N2) influenza virus
Benjavongkulchai et al. An immunogenicity and efficacy study of purified chick embryo cell culture rabies vaccine manufactured in Japan
Irie et al. Efficacy of oral administration of live herpes simplex virus type 1 as a vaccine
Wong et al. Adhesion of Vi antigen and toxicity in typhoid vaccines inactivated by acetone or by heat and phenol
Fitzwilliam et al. Experimental encephalitis caused by herpes simplex virus: comparison of treatment with tilorone hydrochloride and phosphonoacetic acid

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU BR DK FI JP MC NO RO SU US

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB IT LU NL SE